Raghwa Sharma

ORCID: 0009-0005-0231-3427
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • Cancer Genomics and Diagnostics
  • CRISPR and Genetic Engineering
  • Melanoma and MAPK Pathways
  • Virus-based gene therapy research
  • Cancer Mechanisms and Therapy
  • RNA modifications and cancer
  • Cutaneous Melanoma Detection and Management
  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Reproductive Biology and Fertility
  • Cancer-related Molecular Pathways
  • Protein Degradation and Inhibitors
  • Cancer-related molecular mechanisms research
  • Colorectal Cancer Treatments and Studies
  • Sarcoma Diagnosis and Treatment
  • Immunotherapy and Immune Responses
  • Ferroptosis and cancer prognosis
  • RNA and protein synthesis mechanisms
  • Nonmelanoma Skin Cancer Studies
  • PI3K/AKT/mTOR signaling in cancer
  • Polyomavirus and related diseases
  • CAR-T cell therapy research
  • Vascular Malformations and Hemangiomas

Westmead Hospital
2015-2024

The University of Sydney
2013-2024

Western Sydney University
2013-2023

Westmead Institute
2011-2018

St. Vincent's Hospital
2015

St Vincent's Hospital
2015

King Edward Memorial Hospital
2012

The University of Western Australia
2012

Queen Elizabeth II Medical Centre
2012

Royal Prince Alfred Hospital
2004-2012

Abstract Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these been consistently confounded by limitations study design, methodology, and/or heterogeneity sample cohort. High‐grade serous (HGS) carcinoma is most clinically important histological subtype of cancer. As tumours may arise from ovary, Fallopian tube or peritoneum, they are collectively referred to as high‐grade pelvic (HGPSC). To identify true prevalence HGPSC, we sequenced...

10.1002/path.2696 article EN other-oa The Journal of Pathology 2010-02-03

To evaluate the effects of treatment with potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune responses to metastatic melanoma in tissues taken before and after treatment.Thirty-seven tumor biopsies were collected from 15 patients unresectable American Joint Committee Cancer stage III IV immediately approximately 7 days commencement inhibitor at time progression. Immunohistochemical staining was carried out using specific antibodies for CD8, CD4, CD20, CD1a, Granzyme...

10.1158/1078-0432.ccr-11-2479 article EN Clinical Cancer Research 2011-12-13
Ellen L. Goode Matthew S. Block Kimberly R. Kalli Robert A. Vierkant Wenqian Chen and 94 more Zachary C. Fogarty Aleksandra Gentry‐Maharaj Aleksandra Tołoczko Alexander Hein Aliecia L. Bouligny Allan Jensen Ana Osório Andreas D. Hartkopf Andy Ryan Anita Chudecka-Głaz Anthony M. Magliocco Arndt Hartmann Audrey Jung Bo Gao Brenda Y. Hernandez Brooke L. Fridley Bryan M. McCauley Catherine J. Kennedy Chen Wang Chloe Karpinskyj Christiani Bisinoto de Sousa Daniel Guimarães Tiezzi David L. Wachter Esther Herpel Florin‐Andrei Taran Francesmary Modugno Gregg Nelson Jan Lubiński Janusz Menkiszak Jennifer Alsop Jenny Lester Jesús García-Donás Jill Nation Jillian A. Hung José Palacios Joseph H. Rothstein Joseph L. Kelley Jurandyr Moreira de Andrade Luis A. Díaz‐Robles Maria P. Intermaggio Martin Widschwendter Matthias W. Beckmann Matthias Ruebner Mercedes Jimenez‐Liñan Naveena Singh Oleg Oszurek Paul R. Harnett Peter Rambau Hans‐Peter Sinn Philipp Wagner Prafull Ghatage Raghwa Sharma Robert P. Edwards Roberta B. Ness Sandra Oršulić Sara Y. Brucker Sharon E. Johnatty Teri A. Longacre Ursula Eilber Valerie McGuire Weiva Sieh Yanina Natanzon Zheng Li Alice S. Whittemore Anna deFazio Annette Staebler Beth Y. Karlan C. Blake Gilks David D.L. Bowtell Estrid Høgdall Francisco José Cândido dos Reis Helen Steed Ian Campbell Jacek Gronwald Javier Benı́tez Jennifer M. Koziak Jenny Chang‐Claude Kirsten B. Moysich Linda E. Kelemen Linda S. Cook Marc T. Goodman María J. García Peter A. Fasching Stefan Kommoss Suha Deen Susanne K. Kjær Usha Menon James D. Brenton Paul D.P. Pharoah Georgia Chenevix‐Trench David G. Huntsman Stacey J. Winham Martin Köbel Susan J. Ramus

Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns TILs by histotype and relation to other clinical factors.

10.1001/jamaoncol.2017.3290 article EN JAMA Oncology 2017-10-19

Low grade serous ovarian tumours are a rare and under-characterised histological subtype of epithelial tumours, with little known the molecular drivers facilitators tumorigenesis beyond classic oncogenic RAS/RAF mutations. With move towards targeted therapies due to chemoresistant nature this subtype, it is pertinent more fully characterise genetic events driving tumour type, some which may influence response therapy and/or development drug resistance. We performed genome-wide...

10.18632/oncotarget.5438 article EN Oncotarget 2015-10-19

The aim of this study was to investigate the role infiltrating macrophages in renal allograft fibrosis. Forty-six protocol biopsies obtained 1 year after transplantation were stained with Sirius red quantify fibrosis and double CD68 CD206 identify proportion alternatively activated (M2) macrophages. Biopsies analyzed for gene expression by microarray, which correlated macrophage infiltration severity number CD68+ cells strongly percentage interstitial (r = 0.73, p < 0.0001). Macrophage at...

10.1111/ajt.12803 article EN cc-by-nc-nd American Journal of Transplantation 2014-08-06

Low-grade serous ovarian carcinomas (LGSC) are Ras pathway-mutated, TP53 wild-type, and frequently associated with borderline tumors. Patients LGSCs respond poorly to platinum-based chemotherapy may benefit from pathway-targeted agents. High-grade (HGSC) TP53-mutated thought be rarely We sought determine whether histology grade 2 or 3 carcinoma was an indicator of mutation, we explored the molecular relationship between coexisting invasive histologies.We reviewed >1,200 patients identified...

10.1158/1078-0432.ccr-14-1292 article EN Clinical Cancer Research 2014-10-15

Reactivation of BK virus in renal allografts causes a destructive chronic infection. This single-center retrospective cohort study describes the evolution allograft nephropathy (BKVAN) from 63 kidneys (from 61 patients) using sequential histopathology (454 biopsies, averaging 7.8 ± 2.6 per kidney) followed for 60.1 mo. Uninfected protocol biopsies formulated time-matched control Banff scores (n = 975). Interstitial inflammation occurred 73% at diagnosis, correlating with viral (r 0.413, p...

10.1111/ajt.14292 article EN cc-by-nc-nd American Journal of Transplantation 2017-03-31

10.1038/s41379-019-0302-0 article EN publisher-specific-oa Modern Pathology 2019-06-25

Abstract Approximately, 10% to 15% of serous ovarian tumors fall into the category designated as low malignant potential (LMP). Like their invasive counterparts, LMP may be associated with extraovarian disease, for example, in peritoneal cavity and regional lymph nodes. However, unlike typical carcinomas, patients generally have a favorable prognosis. The mutational profile also differs markedly from that seen most carcinomas. Typically, are KRAS BRAF mutations. Interrogation expression...

10.1158/1541-7786.mcr-08-0193 article EN Molecular Cancer Research 2008-11-01

Abstract Purpose: Women with epithelial ovarian cancer generally have a poor prognosis; however, subset of patients has an unexpected dramatic and durable response to treatment. We sought identify clinical, pathological, molecular determinants exceptional survival in women high-grade serous (HGSC), disease associated the majority deaths. Experimental Design: evaluated histories 2,283 and, after applying stringent clinical pathological selection criteria, identified 96 HGSC that represented...

10.1158/1078-0432.ccr-17-1621 article EN Clinical Cancer Research 2017-10-23
Peter Rambau Robert A. Vierkant Maria P. Intermaggio Linda E. Kelemen Marc T. Goodman and 91 more Esther Herpel Paul D.P. Pharoah Stefan Kommoss Mercedes Jimenez‐Liñan Beth Y. Karlan Aleksandra Gentry‐Maharaj Usha Menon Susanna Hernando Polo Francisco José Cândido dos Reis Jennifer A. Doherty Simon A. Gayther Raghwa Sharma Melissa C. Larson Paul R. Harnett Emma Hatfield Jurandyr Moreira de Andrade Gregg Nelson Helen Steed Joellen M. Schildkraut Micheal E Carney Estrid Høgdall Alice S. Whittemore Martin Widschwendter Catherine J. Kennedy Frances Wang Qin Wang Chen Wang Sebastian M. Armasu Frances Daley Penny Coulson Michael E. Jones Michael S. Anglesio Christine Chow Anna de Fazio Montserrat García‐Closas Sara Y. Brucker Cezary Cybulski Holly R. Harris Andreas D. Hartkopf Tomasz Huzarski Allan Jensen Jan Lubiński Oleg Oszurek Javier Benı́tez Fady Mina Annette Staebler Florin‐Andrei Taran J Pasternak Aline Talhouk Mary Anne Rossing Joy Hendley Robert P. Edwards Sián Fereday Francesmary Modugno Roberta B. Ness Weiva Sieh Mona El‐Bahrawy Stacey J. Winham Jenny Lester Susanne K. Kjær Jacek Gronwald Hans‐Peter Sinn Peter A. Fasching Jenny Chang‐Claude Kirsten B. Moysich David D.L. Bowtell Brenda Y. Hernandez Hugh Luk Sabine Behrens Mitul Shah Audrey Jung Prafull Ghatage Jennifer Alsop Kathryn Alsop Jesús García-Donás Pamela J. Thompson Anthony J. Swerdlow Chloe Karpinskyj Alicia Cazorla María J. García Susha Deen Lynne R. Wilkens J.M. Palacios Andrew Berchuck Jennifer M. Koziak James D. Brenton Linda S. Cook Ellen L. Goode David G. Huntsman Susan J. Ramus Martin Köbel

Abstract We aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and explore it other carcinoma histotypes. protein was assessed by clinical‐grade immunohistochemistry 6525 including 4334 HGSC using tissue microarrays from 24 studies participating Ovarian Tumor Tissue Analysis consortium. patterns were interpreted as abnormal (either overexpression referred block or absence) normal (heterogeneous). CDKN2A (which encodes p16) mRNA also...

10.1002/cjp2.109 article EN cc-by The Journal of Pathology Clinical Research 2018-07-31

Targeted therapies are increasingly being used to treat a variety of cancers. Their efficacy depends upon the accurate detection and targeting specific mutation or aberration in tumor. All cancers, such as melanoma, molecularly heterogeneous, with drug-resistant subclones present before treatment emerging result targeted therapies. Here, we show intralesional molecular heterogeneity progressing V600E BRAF-mutant melanoma metastasis from patient treated for 7 months BRAF inhibitor...

10.1158/1535-7163.mct-12-0530 article EN Molecular Cancer Therapeutics 2012-09-08

Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and molecularly characterized by RAS pathway activation. Using exome whole genome sequencing, we identified recurrent mutations in the protein translational regulator EIF1AX NF1, USP9X, KRAS, BRAF, NRAS were mutually exclusive; however, found significant co-occurrence of Missense clustered at N-terminus region its role ensuring initiation fidelity. Coexpression mutant proteins promoted...

10.1158/0008-5472.can-16-2224 article EN Cancer Research 2017-06-24
Aline Talhouk Joshy George Chen Wang Timothy Budden Tuan Zea Tan and 95 more Derek S. Chiu Stefan Kommoss Huei San Leong Stephanie Chen Maria P. Intermaggio C. Blake Gilks Tayyebeh M. Nazeran Mila Volchek Wafaa Elatre Rex C. Bentley Janine Senz Amy Lum Veronica Chow Hanwei Sudderuddin Robertson Mackenzie Samuel C.Y. Leong Geyi Liu Dustin Johnson Billy Chen AOCS Group Jennifer Alsop Susana Banerjee Sabine Behrens Clara Bodelón Alison H. Brand Louise A. Brinton Michael E. Carney Yoke-Eng Chiew Kara L. Cushing‐Haugen Cezary Cybulski Darren Ennis Sián Fereday Renée T. Fortner Jesús García-Donás Aleksandra Gentry‐Maharaj Rosalind Glasspool Teodora Goranova Casey S. Greene Paul Haluska Holly R. Harris Joy Hendley Brenda Y. Hernandez Esther Herpel Mercedes Jimenez‐Liñan Chloe Karpinskyj Scott H. Kaufmann Gary L. Keeney Catherine J. Kennedy Martin Köbel Jennifer M. Koziak Melissa C. Larson Jenny Lester Liz-Anne Lewsley Jolanta Lissowska Jan Lubiński Hugh Luk Geoff Macintyre Sven� Mahner Iain A. McNeish Janusz Menkiszak Nikilyn Nevins Ana Osório Oleg Oszurek José Palacios Samantha Hinsley Celeste Leigh Pearce Malcolm C. Pike Anna Piskorz Isabelle Ray‐Coquard Valerie Rhenius Cristina Rodríguez‐Antona Raghwa Sharma Mark E. Sherman Dilrini De Silva Naveena Singh Hans‐Peter Sinn Dennis J. Slamon Honglin Song Helen Steed Euan A. Stronach Pamela J. Thompson Aleksandra Tołoczko Britton Trabert Nadia Traficante Chiu-Chen Tseng Martin Widschwendter Lynne R. Wilkens Stacey J. Winham Boris Winterhoff Alicia Beeghly‐Fadiel Javier Benı́tez Andrew Berchuck James D. Brenton Robert Brown Jenny Chang‐Claude

Abstract Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation clinical utility has been hindered by nonstandardized methods, which are not applicable in a setting. We sought to generate grade minimal gene set assay classification individual tumor specimens into HGSOC and confirm previously reported subtype-associated...

10.1158/1078-0432.ccr-20-0103 article EN Clinical Cancer Research 2020-06-17

The aim of the present study was to determine whether micromorphometric features positive sentinel lymph nodes (SLNs) from patients with melanoma are useful for predicting further nodal involvement in completion node dissection (CLND) specimens. Of 986 undergoing SLN biopsy between March 1992 and February 2001, 175 (17.7%) had at least 1 140 subsequent CLND specimens available review. Further 24 (17.1%) patients. 8 SLNs that were assessed, presence metastases correlated significantly a tumor...

10.1309/tdwjtr15tdm1tg7q article EN American Journal of Clinical Pathology 2004-10-01

Anti-N-methyl D-aspartate receptor (NMDAR) encephalitis is a recently described severe neurological disorder predominantly affecting young women, which presents with psychosis, memory deficits, seizures, and encephalopathy, often requiring prolonged hospitalization. The condition frequently associated an underlying neoplasm, most ovarian teratoma, in such cases appears to be para-neoplastic, immune-mediated encephalopathy. histologic features of the teratomas anti-NMDAR have seldom been...

10.1097/pgp.0b013e31824a1de2 article EN International Journal of Gynecological Pathology 2012-07-25

Australia has implemented a high‐coverage HPV vaccination program but not, to date, established the distribution of types that occur in cervical cancers Australia. This information is important for determining potential cancer prevention with both current and broader spectrum vaccines. We analysed 847 diagnosed 2005 2015 tertiary centres three most populous Australian states resolution specimens containing multiple using laser‐capture microdissection. Archived FFPE tissue was reviewed by...

10.1002/ijc.30871 article EN International Journal of Cancer 2017-07-05

Inositol pyrophosphates (PP-IPs) comprising inositol, phosphate, and pyrophosphate (PP) are essential for multiple functions in eukaryotes. Their role fungal pathogens has never been addressed. Cryptococcus neoformans is a model pathogenic fungus causing life-threatening meningoencephalitis. We investigate the cryptococcal kinases responsible production of PP-IPs (IP7/IP8) hierarchy PP-IP importance pathogenicity. Using gene deletion inositol polyphosphate profiling, we identified Kcs1 as...

10.1128/mbio.00531-15 article EN cc-by-nc-sa mBio 2015-06-03

Abstract Background ALM201 is a therapeutic peptide derived from FKBPL that has previously undergone preclinical and clinical development for oncology indications completed Phase 1a trial in ovarian cancer patients other advanced solid tumours. Methods In vitro, stem cell (CSC) assays range of HGSOC lines patient samples, vivo tumour initiation, growth delay limiting dilution assays, were utilised. Mechanisms determined by using immunohistochemistry, ELISA, qRT-PCR, RNAseq western blotting....

10.1038/s41416-019-0649-5 article EN cc-by British Journal of Cancer 2019-11-27
Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne and 92 more Tibor A. Zwimpfer Nicola S. Meagher Sián Fereday Laura Twomey Kathleen I. Pishas Therese Hoang Adelyn Bolithon Nadia Traficante Kathryn Alsop Elizabeth L. Christie Eun-Young Kang Gregg Nelson Prafull Ghatage Cheng‐Han Lee Marjorie J. Riggan Jennifer Alsop Matthias W. Beckmann Jessica Boros Alison H. Brand Angela Brooks‐Wilson Michael E. Carney Penny Coulson Madeleine Courtney‐Brooks Kara L. Cushing‐Haugen Cezary Cybulski Mona El‐Bahrawy Esther Elishaev Ramona Erber Simon A. Gayther Aleksandra Gentry‐Maharaj C. Blake Gilks Paul R. Harnett Holly R. Harris Arndt Hartmann Alexander Hein Joy Hendley Brenda Y. Hernandez Anna Jakubowska Mercedes Jimenez-Linan Michael E. Jones Scott H. Kaufmann Catherine J. Kennedy Tomasz Kluz Jennifer M. Koziak Björg Kristjansdottir Nhu D. Le Marcin Lener Jenny Lester Jan Lubiński Constantina Mateoiu Sandra Oršulić Matthias Ruebner Minouk J. Schoemaker Mitul Shah Raghwa Sharma Mark E. Sherman Yurii B. Shvetsov T. Rinda Soong Helen Steed Paniti Sukumvanich Aline Talhouk Sarah E. Taylor Robert A. Vierkant Chen Wang Martin Widschwendter Lynne R. Wilkens Stacey J. Winham Michael S. Anglesio Andrew Berchuck James D. Brenton Ian Campbell Linda S. Cook Jennifer A. Doherty Peter A. Fasching Renée T. Fortner Marc T. Goodman Jacek Gronwald David G. Huntsman Beth Y. Karlan Linda E. Kelemen Usha Menon Francesmary Modugno Paul D.P. Pharoah Joellen M. Schildkraut Karin Sundfeldt Anthony J. Swerdlow Ellen L. Goode Anna deFazio Martin Köbel Susan J. Ramus David D.L. Bowtell Dale W. Garsed

Abstract Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes how co-occurrence BRCA1 or BRCA2 (BRCA) alterations loss influences in tubo-ovarian high-grade serous (HGSC). Experimental Design: protein classified by immunohistochemistry carcinomas 7,436 patients from the Ovarian Tumor Tissue Analysis consortium. We examined germline BRCA status a subset 1,134 HGSC, related genotype overall (OS), tumor-infiltrating CD8+ lymphocytes,...

10.1158/1078-0432.ccr-23-3552 article EN cc-by Clinical Cancer Research 2024-06-05

In a previous immunohistochemical study of dendritic cells (DC) in sentinel lymph nodes (SLN) draining regressing melanomas, we found that the accumulation mature DC-LAMP(+) DCs SLNs was associated with local expansion antigen-specific memory effector CTLs and absence metastasis downstream nodes. The aim this to investigate prognostic importance maximal density SLNs.A total 458 consecutive patients micrometastatic melanoma within were eligible for analysis. evaluated by three independent...

10.1158/1078-0432.ccr-07-0358 article EN Clinical Cancer Research 2007-07-01
Coming Soon ...